Optiscan Imaging (OIL.AX) Osake Kurssi
Optiscan Imaging Kurssi
Optiscan Imagingn liikevaihto on supistunut 12,5 % vuodessa viimeisten 19 vuoden aikana 448 769,00 AUD:een. Optiscan Imagingn nettomarginaali on nyt −1 556,7 %, laskenut −417,9 %:sta muutama vuosi sitten.
Optiscan Imaging osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Optiscan Imaging liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Optiscan Imaging -osakkeesta
The business model of Optiscan Imaging Ltd focuses on developing and commercializing advanced medical imaging technologies. The company specializes in the design and manufacture of confocal laser endomicroscopes, which are used in various medical applications. Optiscan Imaging aims to improve the diagnosis and treatment of diseases through their innovative imaging solutions. By leveraging their expertise in advanced imaging technologies, the company aims to provide healthcare professionals with high-quality and real-time cellular imaging during medical procedures. Optiscan Imaging Ltd's business model is centered around offering cutting-edge medical imaging technologies that deliver precise and detailed cellular imaging for improved patient outcomes.
Optiscan Imaging Ltd is primarily active in the medical technology and healthcare industries.
The main competitors of Optiscan Imaging Ltd in the market include companies such as Carl Zeiss Meditec AG, NIDEK CO., LTD., and Topcon Corporation.
Optiscan Imaging Ltd is a renowned company specializing in medical imaging technologies. Established in [year], Optiscan has achieved significant milestones in the field of diagnostic imaging. The company is known for its innovative optical imaging systems, such as confocal microscopy, which provide high-resolution cellular images for diagnostic purposes. Optiscan Imaging Ltd has a rich history of research and development, consistently striving to push the boundaries of medical imaging. With its advanced imaging solutions, Optiscan continues to contribute to the progression of healthcare.
Optiscan Imaging Ltd has achieved several significant milestones. The company successfully developed and patented a revolutionary confocal endomicroscopy technology, which enables real-time, high-resolution imaging of living tissue. Optiscan Imaging Ltd also received clearance from the U.S. Food and Drug Administration (FDA) for its confocal endomicroscopy system, facilitating its entry into the American market. Furthermore, the company collaborated with renowned medical institutions and researchers worldwide to conduct clinical studies and validate the efficacy of its imaging technology. Optiscan Imaging Ltd's relentless dedication to innovation and research has positioned it as a leader in the field of real-time tissue imaging.
Optiscan Imaging Ltd is primarily present in Australia.
Optiscan Imaging Ltd is a company known for its strong commitment to innovation and excellence in medical imaging. With a vision to improve patient outcomes, Optiscan prides itself on providing cutting-edge solutions for real-time cellular imaging. The company's corporate philosophy revolves around leveraging advanced technology to enhance diagnostic accuracy and enhance the effectiveness of medical procedures. Optiscan Imaging Ltd values integrity, collaboration, and a customer-centric approach, ensuring that their products and services meet the evolving needs of the medical community. By prioritizing research and development, Optiscan aims to revolutionize the field of medical imaging, while maintaining a steadfast dedication to quality and patient care.
Nykyisellä valuuttakurssilla Optiscan Imaging-osake noteerataan hintaan 0,10 EUR (0,16 AUD).
Optiscan Imaging-osake (OIL.AX) on listattuna 1 pörssissä, muun muassa: ASX (OIL.AX).
Optiscan Imaging Ltd is a leading provider of high-quality microscope systems and components for scientific research, medical diagnostics, and industrial testing and quality assurance. The company was founded in Melbourne, Australia in 1994 and has since expanded its operations worldwide. Today, Optiscan Imaging is a global company that delivers innovative technologies and products to meet the needs of its customers in various industries.
liikevaihto Optiscan Imaging on 448 769,00 AUD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
voitto Optiscan Imaging on −6,99 M AUD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Optiscan Imaging:n hinta-voitto-suhde (P/E) on tällä hetkellä −23,91. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Optiscan Imaging-osakkeen arvostusta.
Optiscan Imaging:n hinta-myynti-suhde (P/S) on tällä hetkellä 372,28. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Optiscan Imaging-osakkeen arvostuskennuslukuna.
Optiscan Imaging:n Eulpool-laatuscore on 4/10.
Optiscan Imaging:n ISIN on AU000000OIL4. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Optiscan Imaging:n WKN on 932111. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Optiscan Imaging:n ticker on OIL.AX. Tämä pörssinoteeraus käytetään Optiscan Imaging-osakkeiden kauppaan pörssissä.
Optiscan Imaging osake
Optiscan Imaging vertaisryhmä
Optiscan Imaging Ticker
Optiscan Imaging FIGI
Kaikki tunnusluvut ja syvällinen analyysi Optiscan Imaging:sta
Meidän osakeanalyysimme Optiscan Imaging-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Optiscan Imaging:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: